Physician profile
Howard Eisen
NPI 1225086101
$16,839.30
in general payments reported to CMS, 2019-2025
27 companies · $5,861 in 2025
The $5,861 reported for 2025 was more than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,070 · 2020: $4,800 · 2021: $1,933 · 2022: $448 · 2023: $1,370 · 2024: $1,357 · 2025: $5,861.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,000 · Food and Beverage: $3,588.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,000.00 |
| Food and Beverage | $3,587.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $8,147.57 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Briohealth Solutions, INC. | $5,000.00 | 2025 | Briovad |
| Impulse Dynamics (USA) INC. | $614.22 | 2023-2025 | Optimizer, Optimizer |
| Cvrx, INC. | $524.24 | 2022-2025 | Barostim Neo System |
| Medicure Pharma INC. | $500.00 | 2019 | |
| Becton, Dickinson and Company | $433.33 | 2021 | |
| Eurofins Viracor, LLC | $184.19 | 2019 | |
| Biocardia, INC. | $158.27 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $144.76 | 2019-2025 | Lifevest |
| Takeda Pharmaceuticals U.S.A., INC. | $135.98 | 2022 | |
| Pfizer INC. | $131.00 | 2023-2025 | |
| Medtronic Vascular, INC. | $121.26 | 2019 | |
| One Lambda, INC. | $100.61 | 2024 | |
| Novartis Pharmaceuticals Corporation | $100.49 | 2024-2025 | |
| Amgen INC. | $97.93 | 2023-2025 | Repatha, Repatha |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $97.28 | 2019-2022 | |
| Scpharmaceuticals INC. | $79.55 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.35 | 2024-2025 | Jardiance, Jascayd |
| Abiomed | $46.40 | 2023 | Impella |
| Alnylam Pharmaceuticals INC. | $43.94 | 2025 | Onpattro |
| United Therapeutics Corporation | $25.27 | 2025 | Tyvaso |
| E.R. Squibb & Sons, L.L.C. | $17.68 | 2025 | Eliquis |
| Sanofi-Aventis U.S. LLC | $16.86 | 2019 | |
| Kamada LTD. | $14.29 | 2024 | |
| Vifor Pharma, INC. | $14.21 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $13.62 | 2023 | Farxiga |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Eisen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.